94 related articles for article (PubMed ID: 28752270)
1. Combination treatment with dendrosomal nanocurcumin and doxorubicin improves anticancer effects on breast cancer cells through modulating CXCR4/NF-κB/Smo regulatory network.
Mahjoub MA; Bakhshinejad B; Sadeghizadeh M; Babashah S
Mol Biol Rep; 2017 Aug; 44(4):341-351. PubMed ID: 28752270
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of miR-21 decreases chemotherapeutic effect of dendrosomal curcumin in breast cancer cells.
Esmatabadi MJD; Farhangi B; Montazeri M; Monfared H; Sistani RN; Sadeghizadeh M
Iran J Basic Med Sci; 2017 Apr; 20(4):350-359. PubMed ID: 28804605
[TBL] [Abstract][Full Text] [Related]
3. Enhancing therapeutic efficacy in breast cancer: a study on the combined cytotoxic effects of doxorubicin and MPC-3100.
Gökşen Tosun N
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3249-3259. PubMed ID: 37917369
[TBL] [Abstract][Full Text] [Related]
4. Combined Treatment of Dendrosomal-Curcumin and Daunorubicin Synergistically Inhibit Cell Proliferation, Migration and Induce Apoptosis in A549 Lung Cancer Cells.
Eslami SS; Jafari D; Ghotaslou A; Amoupour M; Asri Kojabad A; Jafari R; Mousazadeh N; Tarighi P; Sadeghizadeh M
Adv Pharm Bull; 2023 Jul; 13(3):539-550. PubMed ID: 37646049
[TBL] [Abstract][Full Text] [Related]
5. GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment.
Zhou Q; Zhou Y; Liu X; Shen Y
Sci Rep; 2017 Oct; 7(1):13379. PubMed ID: 29042665
[TBL] [Abstract][Full Text] [Related]
6. Role of glutaminyl-peptide cyclotransferase in breast cancer doxorubicin sensitivity.
Xu B; Yang L; Yang L; Al-Maamari A; Zhang J; Song H; Wang M; Su S; Song Z
Cancer Biol Ther; 2024 Dec; 25(1):2321767. PubMed ID: 38417050
[TBL] [Abstract][Full Text] [Related]
7. Dendrosomal nanocurcumin prevents EBV-associated cell transformation by targeting the lytic cycle genes of the Epstein-Barr virus in the generation of lymphoblastoid cell line.
Cheragh M; Sadeghizadeh M; Pouriayevali MH; Parsania M
Iran J Basic Med Sci; 2023; 26(10):1220-1226. PubMed ID: 37736518
[TBL] [Abstract][Full Text] [Related]
8. Apatinib increases anticancer potential of doxorubicin in breast cancer cells.
Aghaei E; Soltanzadeh H; Kohan L; Heiat M
Mol Biol Rep; 2023 Dec; 50(12):10137-10145. PubMed ID: 37921980
[TBL] [Abstract][Full Text] [Related]
9. NF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges.
Guo Q; Jin Y; Lin M; Zeng C; Zhang J
Life Sci; 2024 Jul; 348():122684. PubMed ID: 38710275
[TBL] [Abstract][Full Text] [Related]
10. The Transcriptome of BT-20 Breast Cancer Cells Exposed to Curcumin Analog NC2603 Reveals a Relationship between EGR3 Gene Modulation and Cell Migration Inhibition.
Nishimura FG; Sampaio BB; do Couto GO; da Silva AD; da Silva WJ; Peronni KC; Evangelista AF; Hossain M; Dimmock JR; Bandy B; Beleboni RO; Marins M; Fachin AL
Molecules; 2024 Mar; 29(6):. PubMed ID: 38543002
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of ozone with doxorubicin on the proliferation, apoptosis and metastatic profile of luminal-B type human breast cancer cell line.
Karagülle OO; Yurttaş AG
Tissue Cell; 2023 Dec; 85():102233. PubMed ID: 37866151
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effects of Peiminine and Doxorubicin on breast cancer through enhancing DNA damage via ZEB1.
Xu J; Zhang Z; Hu H; Yang Y; Xiao C; Xi L; Lu J; Tian S; Zhao H
Biomed Pharmacother; 2024 Apr; 173():116353. PubMed ID: 38432128
[TBL] [Abstract][Full Text] [Related]
13. Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells.
Huang MB; Giesler KE; Katzman BM; Prosser AR; Truax V; Liotta DC; Wilson LJ; Bond VC
Oncotarget; 2018 Mar; 9(24):16996-17013. PubMed ID: 29682200
[TBL] [Abstract][Full Text] [Related]
14. Amphotericin B potentiates the anticancer activity of doxorubicin on the MCF-7 breast cancer cells.
Tavangar F; Sepehri H; Saghaeian Jazi M; Asadi J
J Chem Biol; 2017 Jul; 10(3):143-150. PubMed ID: 28685000
[TBL] [Abstract][Full Text] [Related]
15. Unveiling the anticancer potential of the ethanolic extract from
Oliveira ACR; De Oliveira FS; Bráz AF; Oliveira JS; Lima-Santos J; Dias AAM
Front Pharmacol; 2024; 15():1398135. PubMed ID: 38751785
[TBL] [Abstract][Full Text] [Related]
16. Dendrosomal nanocurcumin and exogenous p53 can act synergistically to elicit anticancer effects on breast cancer cells.
Baghi N; Bakhshinejad B; Keshavarz R; Babashah S; Sadeghizadeh M
Gene; 2018 Sep; 670():55-62. PubMed ID: 29753810
[TBL] [Abstract][Full Text] [Related]
17. Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.
Fakhri S; Moradi SZ; Faraji F; Farhadi T; Hesami O; Iranpanah A; Webber K; Bishayee A
Cancer Metastasis Rev; 2023 Sep; 42(3):959-1020. PubMed ID: 37505336
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of dendrosomal nanocurcumin and oxaliplatin on oncogenic properties of ovarian cancer cell lines by down-expression of MMPs.
Seyed Hosseini E; Alizadeh Zarei M; Tarrahimofrad H; Zamani J; Haddad Kashani H; Ahmad E; Nikzad H
Biol Res; 2023 Jan; 56(1):3. PubMed ID: 36658640
[TBL] [Abstract][Full Text] [Related]
19. The theranostic potentialities of bioavailable nanocurcumin in oral cancer management.
Essawy MM; Mohamed MM; Raslan HS; Rafik ST; Awaad AK; Ramadan OR
BMC Complement Med Ther; 2022 Nov; 22(1):309. PubMed ID: 36424593
[TBL] [Abstract][Full Text] [Related]
20. Identification of high expression profiles of miR-31-5p and its vital role in lung squamous cell carcinoma: a survey based on qRT-PCR and bioinformatics analysis.
Chi XJ; Wei LL; Bu Q; Mo N; Chen XY; Lan D; Zhou QN
Transl Cancer Res; 2019 Jun; 8(3):788-801. PubMed ID: 35116817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
